Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer

Journal of Clinical Oncology

Volumn 16, Issue 1, 1998, Pages 295-300

  O'Connell, Michael J ^a   Laurie, John A ^b   Kahn, Michael ^b   Fitzgibbons Jr , Robert J ^b   Erlichman, Charles ^b   Shepherd, Lois ^b   Moertel, Charles G ^b   Kocha, Walter I ^b   Pazdur, Richard ^b   Wieand, H Sam ^b   Rubin, Joseph ^b   Vukov, Allen M ^b   Donohue, John H ^b   Krook, James E ^b   Figueredo, Alvaro ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; LEVAMISOLE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STOMATITIS;

EID: 0031982505     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.1.295     Document Type: Article

References (24)

1. Moertel C, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon cancer. N Engl J Med 322:352-358, 1990
2. Moertel CG, Fleming TR, Macdonald JS, et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 122:321-326, 1995
3. Francini G, Petrioli R, Lorenzini L, et al: Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 106:899-906, 1994
4. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345:939-944, 1995
5. Wolmark N, Rockette H, Fisher B, et al: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11:1879-1887, 1993
6. O'Connell MJ, Mailliard JA, Kahn MJ, et al: A controlled trial of 5-fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246-250, 1997
7. NIH Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 2:1444-1450, 1990
8. Keyomarsi K, Moran RG: Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res 46:5229-5235, 1986
9. Rustum YM, Trave F, Zakrewski SF, et al: Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin. NCI Monogr 5:165-170, 1987
10. Park JG, Collins JM, Gazdar AF, et al: Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines. J Natl Cancer Inst 80:1560-1564, 1988
11. Erlichman C, Fine S, Wong A, et al: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6:469-475, 1988
12. Poon MA, O'Connell MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407-1418, 1989
13. Poon MA, O'Connell MJ, Wieand HS, et al: Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:1967-1972, 1991
14. Doroshow JH, Multhauf P, Leong L, et al: Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8:491-501, 1990
15. Petrelli N, Herrera L, Rustum Y, et al: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559-1565, 1987
16. Kovach JS, Svingen PA, Schaid DJ: Levamisole potentiation of fluorouracil antiproliferative activity mimicked by orthovanadate, an inhibitor of tyrosine phosphatase. J Natl Cancer Inst 84:515-519, 1992
17. Buroker TR, O'Connell MJ, Wieand HS, et al: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12:14-20, 1995
18. Becker R, Chambers J, Wilks A: The New S Language. Pacific Grove, CA, Wadsworth & Brooks/Cole, 1988
19. SAS/STAT User's Guide, version 6 ed, vol 2. Cary, NC, SAS Institute, 1990
20. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
21. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Nat Cancer Inst 22:719-748, 1959
22. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-220, 1972
23. Wolmark N, Rockette H, Mamounas EP, et al: The relative efficacy of 5FU + leucovorin, 5 FU + levamisole, and 5FU + leucovorin + levamisole in patients with Dukes' B and C carcinoma of the colon: First report of NSABP C-04. Proc Am Soc Clin Oncol 15:205, 1996 (abstr)
24. Haller DG, Catalano PJ, Macdonald JS, et al: Fluorouracil, leucovorin, and levamisole adjuvant therapy for colon cancer. Proc Am Soc Clin Oncol 15:211, 1996 (abstr)